RxDoctor Payments Data

James Granger, MD

General Practice · Marietta, GANPI 1073714580

Payments from drug & device makers

$769in general payments, 2019–2025

Across 38 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$381
  • Braeburn Inc.$215
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
  • MDD US Operations, LLC$33
  • Masimo Corporation$21
  • Biodelivery Sciences International, Inc.$17
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$768100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$769 in reported general payments places this provider in the 70th percentile of 2,542 general practice providers in Georgia.

See all general practice providers in Georgia

Medicare billing

Part B allowed, 2024
$30,686
Medicare patients
30
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate21$15,239
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen184$5,411
Oxycodone Hcl212$4,673
OxycontinOxycodone Hcl13$3,324
Fentanyl22$1,728
Ondansetron OdtOndansetron64$1,440
Morphine Sulfate32$1,257
Morphine Sulfate ErMorphine Sulfate43$1,187
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl25$1,119
Gabapentin88$1,102
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen45$1,099
Methadone Hcl24$863
Tizanidine Hcl107$788
Hydrocodone-IbuprofenHydrocodone/Ibuprofen13$762
Cyclobenzaprine Hcl105$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine-Naloxone$16$2,37757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,542 general practice providers in Georgia.

Other general practice in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →